Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor
- PMID: 9728551
- DOI: 10.1086/515366
Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor
Abstract
Sexually transmitted diseases, including trichomoniasis, are risk factors for acquisition of human immunodeficiency virus (HIV) infection. Enhancement mechanisms are unknown. Secretory leukocyte protease inhibitor (SLPI) from saliva appears to prevent transmission of HIV through inhibition of virus entry into monocytic cells in vitro. This study was undertaken to determine if secreted cysteine proteases of Trichomonas vaginalis degrade SLPI and render it nonfunctional. It was determined if SLPI levels were decreased in vaginal fluids from pregnant women infected with T. vaginalis. Isolated proteases were incubated with recombinant human SLPI, and the degradation was followed by Western analysis with SLPI antiserum. SLPI levels were measured by ELISA in vaginal fluids from women infected with T. vaginalis and uninfected controls. Cysteine proteases cleaved SLPI and rendered it nonfunctional. Median levels of SLPI from infected patients were 26% of those of controls (P <.005). The degradation of SLPI in association with trichomonal infection may increase the risk of HIV acquisition.
Similar articles
-
Clinical evidence for the role of Trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract.J Infect Dis. 2013 May 1;207(9):1462-70. doi: 10.1093/infdis/jit039. Epub 2013 Jan 25. J Infect Dis. 2013. PMID: 23355743 Free PMC article.
-
Trichocystatin-2 (TC-2): an endogenous inhibitor of cysteine proteinases in Trichomonas vaginalis is associated with TvCP39.Int J Biochem Cell Biol. 2014 Sep;54:255-65. doi: 10.1016/j.biocel.2014.04.005. Int J Biochem Cell Biol. 2014. PMID: 25200185
-
Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.Oral Dis. 1997 May;3 Suppl 1:S64-9. doi: 10.1111/j.1601-0825.1997.tb00377.x. Oral Dis. 1997. PMID: 9456660 Review.
-
Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.Clin Diagn Lab Immunol. 1999 Nov;6(6):808-11. doi: 10.1128/CDLI.6.6.808-811.1999. Clin Diagn Lab Immunol. 1999. PMID: 10548568 Free PMC article.
-
Endogenous salivary inhibitors of human immunodeficiency virus.Arch Oral Biol. 1999 Jun;44(6):445-53. doi: 10.1016/s0003-9969(99)00003-5. Arch Oral Biol. 1999. PMID: 10401522 Review.
Cited by
-
Neonatal and maternal upregulation of antileukoproteinase in horses.Front Immunol. 2024 Apr 26;15:1395030. doi: 10.3389/fimmu.2024.1395030. eCollection 2024. Front Immunol. 2024. PMID: 38736885 Free PMC article.
-
Peptidases Are Potential Targets of Copper(II)-1,10-Phenanthroline-5,6-dione Complex, a Promising and Potent New Drug against Trichomonas vaginalis.Pathogens. 2023 May 22;12(5):745. doi: 10.3390/pathogens12050745. Pathogens. 2023. PMID: 37242415 Free PMC article.
-
Comparison of diagnostic methods and analysis of socio-demographic factors associated with Trichomonas vaginalis infection in Sri Lanka.PLoS One. 2021 Oct 13;16(10):e0258556. doi: 10.1371/journal.pone.0258556. eCollection 2021. PLoS One. 2021. PMID: 34644344 Free PMC article.
-
Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions.Front Immunol. 2019 Aug 28;10:2034. doi: 10.3389/fimmu.2019.02034. eCollection 2019. Front Immunol. 2019. PMID: 31555269 Free PMC article. Review.
-
Trichomoniasis immunity and the involvement of the purinergic signaling.Biomed J. 2016 Aug;39(4):234-243. doi: 10.1016/j.bj.2016.06.007. Epub 2016 Sep 21. Biomed J. 2016. PMID: 27793265 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
